PharmaNutrients sells CLA One to Lipid Nutrition

By Jess Halliday

- Last updated on GMT

Related tags: Lipid nutrition, Conjugated linoleic acid, Linoleic acid, Cla one

PharmaNutrients is exiting the CLA market with the sale of its CLA
One business to Lipid Nutrition and is refocusing its activities on
formulas targeting inflammation, diabetes and cardiovascular

"We have some proprietary positions in those other indications,"​ PharmaNutrients president Mark Nottoli told

Along with Cognis, PharmaNutrients and Lipid Nutrition were both granted licenses to the WARF (Wisconsun Alumni Research Foundation) patent for use of CLA (conjugated linoleic acid) in weight management.

This, said Nottoli, has made it a very competitive market.

"It's not that I don't believe in CLA - I do - but we see more opportunities in areas where we can be proprietary,"​ said Nottoli.

The company's new offerings are not yet ready to be released onto the market, however, and no announcements are expected in the immediate future. In the meantime, its core product is its Absorbitol-branded chitosan.

PharmaNutrients says it was the first company to bring a branded CLA product to market with Tonalin CLA, which it subsequently sold to Cognis. When it developed CLA One DG this was billed as a more effective CLA product enhanced by a diglyceride mechanism.

For Lipid Nutrition, a division of IOI-Loders Croklaan, acquiring PharmaNutrients' business effectively strengthens its position in the world CLA market.

"Lipid Nutrition was the dominant player in the market before, and we still will be,"​ marketing manager John Kurstjens told NutraIngredients-USA.

The company said in a statement that the integration of its Clarinol brand and PharmaNutrient's CLA One brand under one global supplier is beneficial to all customers. But it is not yet clear precisely how the company will manage the brands going forward - whether they will remain discrete or be united under the same name.

"We need to evaluate the brand value and assess the needs of the customers,"​ said Kurstjens.

Although Lipid Nutrition has had a presence in the US market, Clarinol is particularly recognised in Europe. CLA One is also a global brand, but its main market has been the US.

In the US, both companies have warehouse and customer support facilities in the Chicago area, and it is not expected that customers there will experience any changes in supply.

In Europe, however, CLA One customers should see a reduction in delivery times as Lipid Nutrition's processing facility is located in The Netherlands.

Lipid Nutrition does not report its financial results, and Kurstjens was unable to tell how much of its sales are derived from CLA. But he did say that it is its "certainly one of [its] most important products.

Lipid Nutrition's competitive advantage in CLA has been helped by its composition patent, which was granted in Europe in July 2001. Three months prior to being granted it had already been opposed, but the patent office's opposition division concluded that its patent was novel and inventive after minor amendment.

Cognis appealed this decision, however, and Lipid Nutrition only became sure that the patent would remain in force in late 2004, following a decision by the Board of Appeal.

Lipid Nutrition's other branded products are: Safflorin for immune health; Marinol DHA/EPA for cardiovascular health and infant nutrition; Metapol for infant nutrition; Membrinol soybean lecithin for cardiovascular health and memory; and Pinnotin, an appetite suppressant from Korean pine nut.

PharmaNutrients announced last August that it had added another patent to its intellectual property store, on the use of CLA One to prevent or minimize the onset of stress catabolic response in patients who have undergone surgery or suffer from auto-immune disorders and infections.

In February 2005 it filed its first structure-function claims for the body composition benefits of CLA One, and was granted a patent for its combination of CLA with glucosamine and ascorbic acid, used to address inflammation-related disorders.

Related news

Show more

Related products

show more

Clinically Proven Omega-3 formula for Joint Health

Clinically Proven Omega-3 formula for Joint Health

KD Pharma Group | 03-Jun-2019 | Data Sheet

KD Nutra is pleased to announce the completion of a clinical trial for its Move3™ omega-3 joint formulation. The trial has shown that Move3™ has a significant...

Related suppliers

Follow us

Featured Events

View more


View more